Indium-111 Pentetreotide Scintigraphy for Non-Iodine Avid Thyroid Carcinoma
Author Information
Author(s): J Christian, G Cook, C Harmer
Primary Institution: Royal Marsden Hospital
Hypothesis
Can Indium-111 Pentetreotide imaging effectively diagnose and manage non-iodine avid thyroid carcinoma?
Conclusion
Indium-111 Pentetreotide imaging is a useful tool for diagnosing and staging non-iodine avid thyroid carcinoma.
Supporting Evidence
- 6 out of 8 patients with metastatic Hurthle cell carcinoma had positive scans.
- Two patients with localized Hurthle cell carcinoma showed no evidence of residual disease post-scan.
- Positive scans were also observed in patients with medullary and papillary carcinoma.
Takeaway
Doctors used a special scan to find thyroid cancer that doesn't take up iodine, and it worked well for many patients.
Methodology
The study assessed 12 patients with various types of thyroid carcinoma using Indium-111 Pentetreotide scintigraphy and correlated results with conventional radiology.
Limitations
The study had a small sample size and focused only on specific types of thyroid carcinoma.
Participant Demographics
12 patients with histologically proven thyroid carcinoma, including 10 with Hurthle cell carcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website